Provided by Tiger Trade Technology Pte. Ltd.

HENLIUS

69.100
+3.1004.70%
Volume:549.34K
Turnover:37.97M
Market Cap:37.52B
PE:40.44
High:70.400
Open:66.600
Low:66.100
Close:66.000
52wk High:92.000
52wk Low:23.000
Shares:543.00M
HK Float Shares:346.07M
Volume Ratio:1.67
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.709
ROE:23.72%
ROA:4.45%
PB:8.37
PE(LYR):40.44
PS:4.97

Loading ...

China NMPA approves Henlius HLX97 IND for Phase 1 solid tumor trial

Reuters
·
Mar 05

Henlius (02696) Reports Conversion of 182.65 Million Unlisted Shares into H Shares

Bulletin Express
·
Mar 04

Shanghai Henlius Biotech (2696) Schedules Board Meeting for FY2025 Results

Bulletin Express
·
Mar 03

Shanghai Henlius Biotech to Hold Board Meeting on 2025 Final Results and Dividend Recommendation

Reuters
·
Mar 03

Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3%

MT Newswires Live
·
Mar 02

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After Strong 1 Year Total Shareholder Return

Simply Wall St.
·
Mar 01

Shanghai Henlius Biotech (2696) Receives Positive CHMP Opinion for HLX11

Bulletin Express
·
Feb 27

HENLIUS's Biosimilar HLX11 Receives Positive CHMP Review from EMA

Stock News
·
Feb 27

HENLIUS Announces First Patient Dosed in China for Phase 2/3 Trial of HLX22 Plus HLX87 in HER2-Positive Breast Cancer

Stock News
·
Feb 27

Shanghai Henlius Biotech (2696) Doses First Patient in Phase 2/3 Trial for HLX22 + HLX87 in HER2-Positive Breast Cancer

Bulletin Express
·
Feb 27

EMA CHMP issues positive opinion on Shanghai Henlius pertuzumab biosimilar HLX11

Reuters
·
Feb 27

Shanghai Henlius Doses First Patient in Phase 2/3 Trial of HLX22 Plus HLX87 for HER2-Positive Metastatic Breast Cancer in China

Reuters
·
Feb 27

Shanghai Henlius Biotech (2696) Amends Agreements with KGBio and Abbott, Expands HANSIZHUANG Reach

Bulletin Express
·
Feb 24

HENLIUS (02696) Amends Licensing Agreement for HANSIZHUANG® with Abbott and KGBio

Stock News
·
Feb 24

Shanghai Henlius expands HANSIZHUANG licensing partnership with Abbott

Reuters
·
Feb 24

Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation As Shares Show Firm Recent Momentum

Simply Wall St.
·
Feb 16

Shanghai Henlius Biotech, Inc. (2696) Announces FDA Approval of HLX15-SC IND for Multiple Myeloma

Bulletin Express
·
Feb 16

HENLIUS's HLX15-SC for Multiple Myeloma Receives FDA Clearance for Phase 1 Trial

Stock News
·
Feb 16

FDA Approves IND Application for Shanghai Henlius Biotech HLX15-SC in Multiple Myeloma

Reuters
·
Feb 16

Shanghai Henlius Biotech - FDA Approves Ind Application for Hlx15-Sc for Multiple Myeloma

THOMSON REUTERS
·
Feb 16